Apremilast is an oral medication utilized for the treatment of plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behcet's syndrome. As a phosphodiesterase 4 (PDE4) inhibitor, it modulates inflammatory responses, thereby reducing the symptoms of these chronic conditions. Apremilast plays a significant role in managing inflammation and improving the quality of life for patients with these debilitating diseases. In summary, Apremilast effectively alleviates symptoms of psoriasis and psoriatic arthritis.
Apremilast inhibits phosphodiesterase 4, leading to increased levels of cyclic AMP, which subsequently reduces the production of pro-inflammatory cytokines.